Uptravi
| Chemical Name | selexipag |
| Dosage Form | Tablet (oral; 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1000 mcg, 1200 mcg, 1400 mcg, 1600 mcg) |
| Drug Class | Receptor agonists |
| System | Cardiovascular |
| Company | Actelion Pharms Ltd |
| Approval Year | 2015 |
Indication
- For the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH.